article · INTERNATIONAL JOURNAL OF MULTIDISCIPLINARY RESEARCH AND ANALYSIS
Anaemia frequently disrupts and delays chemotherapy administration for cancer patients when low packed cell volume levels are identified. This study investigated disease and treatment variables linked to blood deficits during chemotherapy using secondary data from 145 patient folders in an oncology and palliative care clinic in Nigeria. The findings showed that patients with advanced-stage cancer had a significantly higher demand for blood transfusions than those without advanced disease, at 86.8 per cent compared to 5.6 per cent. Transfusion demand was also significantly higher in patients undergoing seven to ten cycles of chemotherapy, reaching 83.3 per cent, compared to those receiving eleven to fourteen cycles. Although higher demand was observed among patients with sarcomas compared to carcinomas, and among those on single-agent chemotherapy compared to combination chemotherapy, these associations were not statistically significant. Overall, anaemia during cancer therapy relates to both disease complications and chemotherapy toxicity.
Anaemia is a common complication that can interrupt critical chemotherapy schedules. Determining which patients are at greatest risk of requiring blood transfusions helps hospital teams anticipate blood banking needs and plan supportive care. Identifying risk factors such as advanced disease and specific chemotherapy cycles assists oncology units in managing scarce blood supplies and preventing avoidable treatment delays.
The abstract does not indicate an application pathway.
AI-generated from the published abstract. Always read the original work before citing.
Introduction: From time to time, the administration of chemotherapy to patients diagnosed with cancer is delayed partly due to confirmation of anaemia from their PCV test results. Objective: This study aimed to examine the probable disease and treatment related variables that are likely to cause deficit in the percentage level of patients’ blood during the course of receiving chemotherapy. Method: A descriptive-correlation research design was employed with the use of secondary data obtained from 145 patients’ case folders accessed from Medical Record Units in the Department of Oncology and Palliative Care. Results: The findings shows statistically significant correlation for three research questions out of four as; patients with sarcomas had higher demand for blood transfusion compared to those who had carcinomas (30.5% vs 26.5%, p=0.741). Patients with advanced stage cancer disease had higher demand for blood transfusion compared to those who did not have advanced stage cancer (86.8% vs 5.6%, p=0.000). Patients who had 7-10 cycles of chemotherapy had higher demand for blood transfusion with 15(83.3%, p=0.000) than those who had 11-14 cycles of chemotherapy. Lastly, patients who had single-agent chemotherapy had higher demand for blood transfusion than those who had combined chemotherapy agents (30.0% vs 25.3%). But, the correlation was not statistically significant at (p>0.05). Conclusion: Overall, the findings from this study has confirmed evidence from previous studies that incidence of anaemia detected in cancer patients during administration of chemotherapy is often induced by both the patient’s disease complications and noxious effect of chemotherapy agents.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.47191/ijmra/v8-i08-18
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
